Compare FSTR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | RZLT |
|---|---|---|
| Founded | 1902 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.6M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | FSTR | RZLT |
|---|---|---|
| Price | $28.65 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 28.0K | ★ 9.8M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $507,819,000.00 | N/A |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $60.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.16 | $1.07 |
| 52 Week High | $29.40 | $11.46 |
| Indicator | FSTR | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 22.66 |
| Support Level | $26.42 | $1.07 |
| Resistance Level | $27.74 | $1.85 |
| Average True Range (ATR) | 0.94 | 0.64 |
| MACD | 0.14 | -0.97 |
| Stochastic Oscillator | 90.69 | 5.50 |
L.B. Foster Co is a U.S-based firm engaged in the manufacturing, fabrication, and distribution of products and services, especially for the rail, construction, energy, and utility industries. The company operates its business through two segments: Rail Technologies and Services and Infrastructure Solutions. Its principal business activity involves providing new and used rail, trackwork, and accessories, producing concrete railroad ties, insulated rail joints, power rail, track fasteners, cover boards, and sales of sells and rents steel sheet piling, H-bearing pile, and other piling products for foundation and earth retention requirements. It generates the majority of its revenues from the Rail Technologies and Services segment.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.